...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Biogen looks to FDA for approval of early Alzheimers drug.

Bear,

you don't give weight to the "rigorous academic requirements in confirming the primary endpoint" quote from Don McCaffrey in his Sept 30 conference call? 

I interpreted that to suggest that the trial failed on purely statistical grounds...i.e. more patient years would have got us to meeting endpoints.  How else can one interpret it?

Iconoclast

 

 

Share
New Message
Please login to post a reply